US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
(TSV:
NRX
)
0.6400
UNCHANGED
Delayed Quote
Updated: 9:30 AM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NRX
InvestorNewsBreaks – NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) to Highlight Exosome Technology, Pipeline and US Initiatives at NY Conference
September 01, 2026
Via
Investor Brand Network
BioMedNewsBreaks — NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) Wins BOLD Awards VII Healthcare Honor, Engages IBN For Investor Outreach
April 02, 2026
Via
Investor Brand Network
NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock
March 10, 2025
Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - March 10, 2025) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90)...
Via
Newsfile
The Watchlist by The Market Herald Releases New Interviews with NurExone Biologic and SuperBuzz Discussing Their Latest News
September 13, 2023
Via
ACCESSWIRE
NurExone Announces Letter of Intent for International Strategic Collaboration with denovoMATRIX Towards Large-Scale Exosome Production
September 07, 2022
Calgary, Alberta, Canada and Dresden, Germany--(Newsfile Corp. - September 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the...
Via
Newsfile